Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Q Biomed Inc (QBIO)

Q Biomed Inc (QBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 7,190
  • Shares Outstanding, K 16,721
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,270 K
  • 60-Month Beta 3.85
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.68
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/01/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 11/30/19
See More
  • Average Estimate -0.12
  • Number of Estimates 1
  • High Estimate -0.12
  • Low Estimate -0.12
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3500 +11.11%
on 11/07/19
0.5300 -26.62%
on 10/16/19
-0.1311 (-25.21%)
since 10/14/19
3-Month
0.3500 +11.11%
on 11/07/19
1.1000 -64.65%
on 08/16/19
-0.7111 (-64.65%)
since 08/14/19
52-Week
0.3500 +11.11%
on 11/07/19
2.5400 -84.69%
on 01/25/19
-1.7311 (-81.66%)
since 11/14/18

Most Recent Stories

More News
Innovative Biotechs Look to Tackle Ocular Ailments

Visual impairment is one of the most common health conditions that negatively impact millions of Americans' physical and mental health. Visual impairment is defined as 20/40 vision, or worse, in the better...

QBIO : 0.3889 (-9.56%)
JNJ : 130.96 (-0.24%)
AGN : 182.47 (+0.48%)
BHC : 27.75 (+1.35%)
AERI : 18.23 (-3.03%)
Biotechs Target Innovative Advances in the Battle Against Cancer

Cancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In 2018, the World Cancer Research Fund (WCRF) estimated that there were 18...

CELGZ : 0.48 (unch)
QBIO : 0.3889 (-9.56%)
CELG : 110.02 (-0.35%)
GILD : 63.81 (+0.76%)
MRK : 84.55 (-0.32%)
PFE : 36.55 (-0.14%)
Q BioMed Announces $7.5M Grant Benefiting its Preclinical Product Development Pipeline

NEW YORK , Nov. 5, 2019 /PRNewswire/ --  Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, announced today that its technology partner, Mannin , has received...

QBIO : 0.3889 (-9.56%)
Patients Demand Personalized Treatments for Cancer as Death Rates Soar

Cancer is ranked among the top causes of death globally, and recent data indicates that the number of cancer related cases is only expected to rise. As a result, the global cancer therapeutics market is...

QBIO : 0.3889 (-9.56%)
ABBV : 87.63 (+1.12%)
SGEN : 113.29 (+0.96%)
MRK : 84.55 (-0.32%)
GSK : 43.85 (-1.81%)
Q BioMed Announces Commercial Partnership With Jubilant Radiopharma for the Distribution of its Non-Opioid Cancer Palliation Drug in the United States

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today it has entered into an exclusive distribution agreement for its non-opioid metastatic cancer pallion drug, Strontium-89...

QBIO : 0.3889 (-9.56%)
Q BioMed Announces Commercial Partnership With Jubilant Radiopharma for the Distribution of its Non-Opioid Cancer Palliation Drug in the United States

NEW YORK , Oct. 3, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, announced today it has entered into an exclusive distribution agreement...

QBIO : 0.3889 (-9.56%)
Q BioMed Announces Legal Settlement and Acquisition of FDA Approved Non-Opioid Metastatic Cancer Pain Drug

Q BioMed Inc. (OTCQB: QBIO), is pleased to report that it has entered into a settlement agreement with BioNucleonics Inc. to complete the outright acquisition of the non-opioid cancer bone pain drug Strontium-89...

QBIO : 0.3889 (-9.56%)
Q BioMed Announces Legal Settlement and Acquisition of FDA Approved Non-Opioid Metastatic Cancer Pain Drug

NEW YORK , Oct. 2, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO),  is pleased to report that it has entered into a settlement agreement with BioNucleonics Inc. to complete the outright acquisition...

QBIO : 0.3889 (-9.56%)
Q Biomed and Collaborator Chemveda Life Sciences Enter Agreement for Synthesis and Manufacturing of Liver Cancer Chemotherapeutic

Q BioMed, Inc. (OTCQB: QBIO) and Chemveda Life Sciences are very pleased to announce that after the recent successful chemical synthesis of a unique natural compound that has shown remarkable efficacy...

QBIO : 0.3889 (-9.56%)
Q Biomed and Collaborator Chemveda Life Sciences Enter Agreement for Synthesis and Manufacturing of Liver Cancer Chemotherapeutic

QBIO : 0.3889 (-9.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade QBIO with:

Key Turning Points

2nd Resistance Point 0.4796
1st Resistance Point 0.4343
Last Price 0.3889
1st Support Level 0.3493
2nd Support Level 0.3096

See More

52-Week High 2.5400
Fibonacci 61.8% 1.7034
Fibonacci 50% 1.4450
Fibonacci 38.2% 1.1866
Last Price 0.3889
52-Week Low 0.3500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar